中国肿瘤生物治疗杂志2018，Vol.25Issue(4)：321-328,8.DOI:10.3872/j.issn.1007-385x.2018.04.001
成胶质细胞瘤CAR-T免疫治疗的研究进展
Research progress on chimeric antigen receptor-engineered T cells for immunotherapy of glioblastoma
摘要
Abstract
Glioblastoma multiforme (GBM) is a malignant tumor of central nervous system with high incidence,aggressive and poor prognosis.Since temozolomide was approved by FDA in 2005,there is no new curative strategy with obvious improvement in therapeutic effect.With the developments in molecular biology,tumor immunology and immunotherapy technology,the discovery of new molecular targets,breakthrough in central immunization exemption theory,and advance in gene transduction and cell technology,GBM immunotherapy ushered in a new breakthrough in immunotherapy.Cellular immunotherapy,presented by chimeric antigen receptor-modified T cell (CAR-T) therapy,has exhibited its prominent application prospect in GBM in vitro experiments targeting EGFRvⅢ,IL-13Rα2,HER2,erythropoietin-producing hepatocellular carcinoma A2 (EphA2),animal models and early clinical trials.However,the GBM molecular heterogeneity,immunosuppressive microenvironment and blood-brain barrier have presented challenge for CAR-T going into the first-line clinical treatment.Researchers are now exploring key antigens of oncogenic phenotype,designing optimal combination of target antigens to prevent the immune escape,improving CAR-T passing through blood-brain barrier and invading tumor tissue,finding the best route for cell deliver,and optimizing evaluation system for central nervous system (CNS) immunotherapy.It is believed that the breakthrough of CAR-T cell immunotherapy will finally help GBM patients pursuing a beautiful life.关键词
成胶质细胞瘤/免疫治疗/嵌合抗原受体Key words
glioblastoma/immunotherapy/chimeric antigen receptor分类
医药卫生引用本文复制引用
石璐璐,韩双印..成胶质细胞瘤CAR-T免疫治疗的研究进展[J].中国肿瘤生物治疗杂志,2018,25(4):321-328,8.基金项目
国家自然科学基金资助项目(No.81172415,No.81372405,No.81772670). Project supported by the National Natural Science Foundation of China(No.81172415,No.81372405,No.81772670) （No.81172415,No.81372405,No.81772670）
